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Abstract
To determine the role of neutrophils in the pathogenesis of hepatic ischemialreperfusion injury livers from male Fischer rats were subjected to 45 mm of no-flow ischemia followed by reperfusion for up to 24 h. Two phases of liver injury were identified, an initial phase during 
Monoclonal antibody
Monoclonal antibodies were prepared against rat neutrophilsby immunizing BALB/c mice with neutrophils obtained from glycogen-induced peritoneal exudate. Hybridomas were produced as previously described (22, 23) and screened using flow cytometry. Three antibodies were selected that bound to rat neutrophils but not mononuclear cells or platelets. Of these, one clone (1F12) was chosen for the present study because it produced sustained neutropenia when given i.v. at a dose of 2 mg/kg.
Animals Male
Fischer-344 rats (250-290 g) were purchased from Harlan Sprague Dawley, Inc. (Houston, Tex.) and allowed free access to food (Purina 5001 rodent chow) and tap water. Animals that were fed were used in all experiments.
Some animals were pretreated with the antibody 1F12 diluted in saline (0.79 mg/mI). For the ischemia experiments, ratswere pretreated with either a singledose (1 mg/kg; i.v.) 30 mm before ischemia or two doses of 2 mg/kg (i.v.); the first injection was 30 mm before ischemia and the second dose was after 5 h of reperfusion.
Hepatic ischemia/reperfusion experiments
Ischemia/reperfusion experiments were performed as described in detail(14).The animals were anesthetized with pentobarbital (50 mg/kg i.p.) and the blood vessels supplying the median and leftlateral hepatic lobes were occluded with an arterial clamp for 45 mm. Reflow was initiated by removal of the clamp. The incision was closed with 3-0 silk and wound clips, and the animals were allowed to recover. Groups of animals were killed before ischemia, at the end of the ischemic period, and after 1, 6, and 24 h of reperfusion.
At the end of the experiment a blood sample was obtained from the right ventricle to determine alanine aminotransferase activity (ALT), and a sample of a nonischemic lobe and a postischemic lobe was freeze-clamped and stored in liquidnitrogen; another sample was fixedin phosphatebuffered formalin.
Glycogen peritonitis experiments
Animals received an i.p.injectionof glycogen (1 g/kg) in sterile salineunder lightether anesthesia.After 6 h, the animals were killedand the peritoneal cavity was lavaged with 10 ml of phosphate-buffered saline. in the postischemic lobes at the end of the experiment correspond to a PMN-to-hepatocyte ratioof about 1:10.Before ischemia, the ratio was about 1:1000. Neutrophils also accumulated in the nonischemic lobes during the To test whether PMNs actively contribute to the reperfusion injury in the liver the monoclonal antibody 1F12 was administered i.v. In control animals (as shown in Fig. 1 At first animals were pretreated with a singledose of 1F12. As shown in Table 2 , the pretreatment regimen reduced the number of PMNs in the tissueby 65% but was only moderately effective in preventing reperfusion injury.Although the histologicalexamination revealed slightlylessnecrotic tissue,plasma ALT activities were not different and the liver ATP content was still reduced by 50% compared with the nonischemic lobes as in the disease control group. However, when the dose of the monoclonal antibody was increased to 2 x 2 mg/kg, the number of PMNs in the liverwas further at- Table  2 ). The liver ATP content of the postischemic lobes was similar to the nonischemic lobes (1.80 ± 0.05 tmol/g liver wt) in the antibodypretreated group. Because only a dose of 1F12 that caused a consistentneutropenia proved to be protective against hepatic reperfusion injury, the antiinflammatory potential of this antibody was evaluated using glycogen-induced peritonitis. As shown in Fig. 2 
Values are means ± SE with a = 6 animals per group. The two vehicle-treated control groups were combined in one control group. Plasma alanine aminotrarisferase activity (ALT), the number of accumulating PMNs in the liver (50 high-power fields counted), the percentage of necrotic tissue, and the hepatic ATP content were determined after 45 mm of hepatic no-flow ischemia and 24 h reperfusion. Animals were pretreated with the anti-neutrophil monoclonal antibody lFl2 (i.v.), with a dose of 1 mg/kg 30 mm before ischemia or 2 x 2 mg/kg 30 mm before ischemia and 6 h after the first dose.
Control groups received 200 1d saline at the same time.
bNumber of animals appears in parenthesis.
'P < 0.05 (controls vs. pretreated groups). observed two phases of liver injury, an initial phase during the first hour of reperfusion and a second phase after 6 h of reperfusion ( 
